ArticlePediatric research2026
Circulating miRNAs as potential liquid biomarkers for pediatric gliomas.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Liquid Biopsy in Primary CNS Tumors: Bridging Biology, Technology, and Clinical Care.Molecular diagnosis & therapy · 2026Review
- Tumor extracellular vesicle RNA profiling predicts treatment response in pediatric diffuse midline glioma.bioRxiv : the preprint server for biology · 2026Article
- MicroRNAs as diagnostic prognostic and therapeutic biomarkers in glioblastoma.Discover oncology · 2026Review
- Review
- The use of plasma miRNAs to better manage pediatric brain gliomas.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent diagnostic and monitoring of pediatric brain tumors rely on invasive tissue biopsies and imaging, highlighting the need for non-invasive alternatives. For that matter, liquid biopsy is a promising method. This pilot study investigated the potential of circulating miRNAs to serve as non-invasive biomarkers of pediatric glioma tumors.
methodsThe levels of mir-182-5p, mir-10b-5p, mir-106b-3p, mir-25-3p, and mir-21-5p were quantified in plasma samples from 68 pediatric gliomas patients and 12 Healthy controls using Real-time PCR. The results were assessed by differential and ROC curve analysis. Additionally, the involvement of mir-182-5p in pediatric high-grade gliomas aggressiveness was examined by functional studies using two cellular models.
resultsAll five circulating miRNAs demonstrated increased levels in pediatric glioma patients compared to HCs, significant correlation with Gliomas, and differential expression between various glioma subtypes. These miRNAs presented potential diagnostic discrimination between HCs and pediatric gliomas, as well as between different glioma subgroups. mir-182-5p showed the highest correlation to glioma and induction of migration as well as invasion ability of pediatric diffuse high-grade glioma 4 (pHGG-4) cells in vitro.
conclusionsOur findings present circulating miRNAs as promising biomarkers and treatment targets that, with further research, may be clinically utilized for monitoring pediatric glioma tumors. IMPACT: This study demonstrates the potential of circulating miRNAs as valuable biomarkers for pediatric glioma detection and monitoring. Five examined circulating miRNAs were differentially expressed in pediatric glioma patients compared to controls. These miRNAs were correlated with glioma and could distinguish healthy from gliomas patients. Statistical analysis suggested these miRNAs may also distinguish between various glioma subtypes. Inhibition of the most promising circulating miRNA, miR-182-5p, decreased migration ability and invasiveness of pediatric high-grade glioma IV cells. In the future, the miRNAs studied could have applications as biomarkers for clinical management and treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.